Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 1998

View Archived Issues

Dornier's BPH device approved by FDA

Biomira updates shareholders at annual general meeting

Aastrom Biosciences receives SBIR grant for dendritic cell expansion technology research

Argonex raises funds for cancer vaccine programs

Dura and Spiros provide development update on asthma products

Urinary reflux product enters phase III

Genome Therapeutics reaches milestone in Schering-Plough alliance

Initiation of late-stage Avicine clinical trial

Access and Block Drug sign agreement for international rights to amlexanox

Molecules to Market changes name

Sertoli Technologies issued second U.S. patent for Sertoli-based cell therapies

Hemosol advances blood substitute in clinical studies for several indications

Procept's PRO-2000 gel protects against herpes infection in mice

Flavopiridol induces apoptosis, regression of human hematological malignancies

17beta-HSD type 1 inhibitors: a new treatment option for hormone-dependent breast cancer

Abbott and Boehringer Ingelheim sign comarketing agreement

PNU-151774E, a safe and effective anticonvulsant in preclinical testing

Procter & Gamble R&D on metalloprotease inhibition

Perimidine-based CRF antagonists developed at Agouron

BMS prepares novel sulfenamide taxane derivatives

Byk Gulden patents another series of thiazole PDE IV inhibitors

Antitumor, antifungal cryptophycins developed by U.S. pharmaceutical/academic team

Lactadherin protects against symptomatic rotavirus infection in infants

No-approval recommendation given for AD-32 by FDA advisory committee

Large U.S. trial confirms high efficacy rate of mifepristone + misoprostol in early pregnancy

Rebetron now available in the U.S.

U.K. launch of Zoladex for assisted conception

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...